Checkpoint inhibitors targeting PD-1 or PD-L1 (e.g., atezolizumab, nivolumab) have demonstrated clinical benefit in a subset of bladder cancer patients, particularly those with high tumor mutational burden (TMB), pre-existing TILs, and elevated IFN-γ signatures (46). Here, IFNG is linked to urinary bladder carcinoma.